Korsana Biosciences Closes Cyclerion Merger, Raises $380M
Korsana Biosciences sealed its merger with Cyclerion Therapeutics and locked in $380M to push its Alzheimer's drug toward clinical trials.
Korsana Biosciences just made a major move. The company closed its merger with Cyclerion Therapeutics and completed a $380 million private placement — real money that signals serious conviction from backers betting on its lead Alzheimer's program.
The asset to watch is KRSA-028. That's the compound Korsana is racing toward the clinic, and the timeline is tighter than you might expect for early-stage biotech. Phase 1 healthy volunteer data is penciled in for mid-2027, giving the market a hard catalyst to trade around.
Read more Apple's Foldable iPhone Duo Arrives — Don't Expect a Stock Surge →
The bigger catalyst comes shortly after. Interim proof-of-concept data in actual Alzheimer's patients is expected by year-end 2027 or the first quarter of 2028. If those readouts show signal, the stock conversation changes fast. If they don't, $380M only goes so far.
The Cyclerion merger brings additional scientific infrastructure into the fold, and the combined entity now has the runway to execute without immediate dilution pressure — assuming burn stays in check. For biotech traders, the clock starts now: roughly two years to the first human data drop.
This is a high-risk, high-reward setup with defined timelines. Watch the mid-2027 Phase 1 readout as your first real tell. Continue reading at GlobalNewswire.
